Results · Jan-Mar 2026 · filed 29 May 2026
3B BlackBio Dx Q4 FY26 results
Sales grew 58% to ₹35.4 crore from ₹22.5 crore in Jan-Mar 2025.
Operating profit grew 7% to ₹8.5 crore, an operating margin of 24.0% (down 11.2 points from a year ago).
Net profit grew 22% to ₹9.8 crore from ₹8 crore in Jan-Mar 2025.
Against Oct-Dec 2025: sales −30%, net profit −56%.
Get 3B BlackBio Dx's next results & call in your inbox, the day they're filed.
Free. One short email on the days it files or its shares make a big move, nothing on other days. Unsubscribe in one click.
Jan-Mar 2026 vs a year ago
| ₹ crore | Jan-Mar 2026 | Jan-Mar 2025 | Change |
|---|---|---|---|
| Sales | 35.4 | 22.5 | +58% |
| Operating profit (EBITDA) | 8.5 | 7.9 | +7% |
| Operating margin | 24.0% | 35.2% | −11.2 pts |
| Net profit | 9.8 | 8.0 | +22% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 8 quarters
Filings that week
- 3 Jun 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 1 Jun 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 30 May 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 29 May 2026Announcement under Regulation 30 (LODR)-Dividend Updates
- 29 May 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 29 May 2026Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended On 31St March, 2026
- 29 May 2026Board Meeting Outcome for Outcome Of Board Meeting
- 26 May 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.